IL204547A - Oracil derivative for the treatment of hepatitis c - Google Patents
Oracil derivative for the treatment of hepatitis cInfo
- Publication number
- IL204547A IL204547A IL204547A IL20454710A IL204547A IL 204547 A IL204547 A IL 204547A IL 204547 A IL204547 A IL 204547A IL 20454710 A IL20454710 A IL 20454710A IL 204547 A IL204547 A IL 204547A
- Authority
- IL
- Israel
- Prior art keywords
- treating hepatitis
- uracil derivative
- uracil
- derivative
- hepatitis
- Prior art date
Links
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical class O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 title 1
- 208000006454 hepatitis Diseases 0.000 title 1
- 231100000283 hepatitis Toxicity 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97287707P | 2007-09-17 | 2007-09-17 | |
| US9679108P | 2008-09-13 | 2008-09-13 | |
| PCT/US2008/076576 WO2009039127A1 (en) | 2007-09-17 | 2008-09-17 | Uracil or thymine derivative for treating hepatitis c |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL204547A0 IL204547A0 (en) | 2010-11-30 |
| IL204547A true IL204547A (en) | 2016-04-21 |
Family
ID=39948002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL204547A IL204547A (en) | 2007-09-17 | 2010-03-16 | Oracil derivative for the treatment of hepatitis c |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US8415351B2 (OSRAM) |
| EP (2) | EP2222646B1 (OSRAM) |
| JP (2) | JP5734654B2 (OSRAM) |
| KR (2) | KR101660360B1 (OSRAM) |
| CN (2) | CN102746239B (OSRAM) |
| AR (2) | AR070027A1 (OSRAM) |
| AU (1) | AU2008302448B2 (OSRAM) |
| BR (1) | BRPI0816994B8 (OSRAM) |
| CA (2) | CA2976793A1 (OSRAM) |
| CL (2) | CL2008002794A1 (OSRAM) |
| CO (1) | CO6260076A2 (OSRAM) |
| CR (2) | CR11316A (OSRAM) |
| DO (2) | DOP2010000084A (OSRAM) |
| ES (1) | ES2453591T3 (OSRAM) |
| GT (1) | GT201000061A (OSRAM) |
| IL (1) | IL204547A (OSRAM) |
| IN (1) | IN2012DN05113A (OSRAM) |
| MX (2) | MX2010002905A (OSRAM) |
| MY (1) | MY162760A (OSRAM) |
| NZ (3) | NZ618277A (OSRAM) |
| PA (1) | PA8796201A1 (OSRAM) |
| PE (2) | PE20090705A1 (OSRAM) |
| PH (1) | PH12013500365A1 (OSRAM) |
| RU (2) | RU2543620C2 (OSRAM) |
| SG (1) | SG183733A1 (OSRAM) |
| TW (2) | TWI534137B (OSRAM) |
| UA (1) | UA117800C2 (OSRAM) |
| UY (1) | UY31344A1 (OSRAM) |
| WO (1) | WO2009039127A1 (OSRAM) |
| ZA (2) | ZA201204223B (OSRAM) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2222646B1 (en) | 2007-09-17 | 2014-01-22 | AbbVie Bahamas Ltd. | Uracil or thymine derivative for treating hepatitis c |
| DK2203431T3 (da) | 2007-09-17 | 2011-11-21 | Abbott Lab | Antiinfektiøse pyrimidiner og anvendelser heraf |
| CA2699989C (en) | 2007-09-17 | 2014-03-25 | Abbott Laboratories | N-phenyl-dioxo-hydro pyrimidines useful as hepatitis c virus (hcv) inhibitor |
| US8765757B2 (en) * | 2007-11-16 | 2014-07-01 | Merck Sharp & Dohme Corp. | 3-heterocyclic substituted indole derivatives and methods of use thereof |
| CN102099335A (zh) | 2008-07-23 | 2011-06-15 | 弗·哈夫曼-拉罗切有限公司 | 杂环抗病毒化合物 |
| MX2011002846A (es) | 2008-09-26 | 2011-04-07 | Hoffmann La Roche | Derivados de pirina o pirazina para tratar el virus de la hepatitis c. |
| NZ594923A (en) * | 2009-03-24 | 2013-11-29 | Abbott Lab | Process for preparing antiviral compound |
| RU2552533C2 (ru) * | 2009-03-25 | 2015-06-10 | Эббви Инк. | Противовирусные соединения и их применения |
| EP2411007A4 (en) * | 2009-03-27 | 2012-12-05 | Uab Research Foundation | MODULATION OF IRES-MEDIATED TRANSLATION |
| SG175774A1 (en) | 2009-04-25 | 2011-12-29 | Hoffmann La Roche | Heterocyclic antiviral compounds |
| AR077004A1 (es) | 2009-06-09 | 2011-07-27 | Hoffmann La Roche | Compuestos heterociclicos antivirales |
| BRPI1011744A2 (pt) | 2009-06-24 | 2016-03-22 | Hoffmann La Roche | composto antiviral heterocíclico. |
| JP2011057661A (ja) * | 2009-08-14 | 2011-03-24 | Bayer Cropscience Ag | 殺虫性カルボキサミド類 |
| MX2012003170A (es) | 2009-09-21 | 2012-04-11 | Hoffmann La Roche | Compuestos heterociclicos antivirales. |
| EP2501679A1 (en) * | 2009-11-21 | 2012-09-26 | F. Hoffmann-La Roche AG | Heterocyclic antiviral compounds |
| WO2011073114A1 (en) | 2009-12-14 | 2011-06-23 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| US9216952B2 (en) | 2010-03-23 | 2015-12-22 | Abbvie Inc. | Process for preparing antiviral compound |
| CN102971305B (zh) | 2010-07-07 | 2016-02-03 | 弗·哈夫曼-拉罗切有限公司 | 抗病毒的杂环化合物 |
| SG10201505540SA (en) | 2010-07-16 | 2015-08-28 | Abbott Lab | Process for preparing antiviral compounds |
| US8975443B2 (en) | 2010-07-16 | 2015-03-10 | Abbvie Inc. | Phosphine ligands for catalytic reactions |
| AU2015201698B2 (en) * | 2010-07-16 | 2017-02-02 | Abbvie Ireland Unlimited Company | Process for preparing antiviral compounds |
| UA113498C2 (xx) | 2010-07-16 | 2017-02-10 | Фосфінові ліганди для каталітичних реакцій | |
| US9255074B2 (en) | 2010-07-16 | 2016-02-09 | Abbvie Inc. | Process for preparing antiviral compounds |
| RU2436786C1 (ru) * | 2010-07-23 | 2011-12-20 | Александр Васильевич Иващенко | Замещенные индолы, противовирусный активный компонент, способ получения и применения |
| WO2012020725A1 (ja) * | 2010-08-10 | 2012-02-16 | 塩野義製薬株式会社 | Ｎｐｙ ｙ５受容体拮抗作用を有するヘテロ環誘導体 |
| BR112013003113A2 (pt) | 2010-08-13 | 2019-09-24 | Hoffmann La Roche | compostos antivirais heterocíclicos |
| CN102675092B (zh) * | 2011-03-14 | 2014-11-05 | 江苏中丹药物研究有限公司 | 一种制备2-芳基-2,2-二甲基乙酸甲酯的方法 |
| CA2829768A1 (en) | 2011-03-18 | 2012-09-27 | Abbvie Inc. | Formulations of phenyl uracil compounds |
| CN103764169B (zh) * | 2011-03-31 | 2017-06-13 | 康斯坦策·沙费尔 | 用于非病毒转移核酸的全氟化化合物 |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| JP5734124B2 (ja) * | 2011-07-21 | 2015-06-10 | 株式会社 東邦アーステック | １，３−ジヨードヒダントイン類の製造方法 |
| EP2740728A4 (en) | 2011-08-01 | 2015-04-01 | Sumitomo Dainippon Pharma Co Ltd | URACIL DERIVATIVE AND ITS USE FOR MEDICAL PURPOSES |
| AU2015200715A1 (en) * | 2011-10-21 | 2015-03-05 | Abbvie Ireland Unlimited Company | Methods for treating HCV |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| US8492386B2 (en) * | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| AU2013201406B2 (en) | 2011-10-21 | 2014-10-02 | Abbvie Ireland Unlimited Company | Methods for treating HCV |
| EP2583680A3 (en) | 2011-10-21 | 2013-06-12 | Abbvie Inc. | Mono (PSI-7977) or combination treatment of DAAs for use in treating HCV |
| BR112014027181A2 (pt) | 2012-05-15 | 2017-06-27 | Novartis Ag | derivados de benzamida para a inibição da atividade de abl1, abl2 e bcr-abl1 |
| ES2665539T3 (es) | 2012-05-15 | 2018-04-26 | Novartis Ag | Derivados de benzamida para inhibir la actividad de ABL1, ABL2 y BCR-ABL1 |
| PL2861579T3 (pl) | 2012-05-15 | 2018-07-31 | Novartis Ag | Pochodne benzamidu do hamowania aktywności ABL 1, ABL 2 i BCR-ABL 1 |
| CA2870339C (en) | 2012-05-15 | 2020-06-02 | Novartis Ag | Compounds and compositions for inhibiting the activity of abl1, abl2 and bcr-abl1 |
| US20140024613A1 (en) | 2012-06-27 | 2014-01-23 | Abbvie Inc. | Methods for Treating HCV |
| EP2887941B1 (en) | 2012-08-21 | 2018-07-11 | AbbVie Ireland Unlimited Company | Process for preparing antiviral compounds |
| MX2015004973A (es) | 2012-10-18 | 2015-07-17 | Abbvie Inc | Formulaciones de compuestos derivados de pirimidindiona. |
| JP2014101316A (ja) * | 2012-11-20 | 2014-06-05 | Toyobo Co Ltd | ベンゾ［１，２−ｄ；４，５−ｄ’］ビスチアゾール化合物の製造方法 |
| EP3016651A1 (en) | 2013-07-02 | 2016-05-11 | AbbVie Inc. | Methods for treating hcv |
| EP3019481B1 (de) | 2013-07-08 | 2019-03-06 | Bayer CropScience Aktiengesellschaft | Sechsgliedrige c-n-verknüpfte arylsulfid- und arylsulfoxid- derivate als schädlingsbekämpfungsmittel |
| ES2927955T3 (es) | 2013-09-11 | 2022-11-14 | Univ Emory | Composiciones de nucleótidos y nucleósidos y sus usos |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
| WO2015116594A1 (en) | 2014-01-28 | 2015-08-06 | Abbvie Inc. | Dose adjustment in combination therapy of hepatitis c |
| EA031804B1 (ru) | 2014-02-03 | 2019-02-28 | Вайтаи Фармасьютиклз, Инк. | Дигидропирролопиридиновые ингибиторы ror-гамма |
| WO2015197028A1 (en) * | 2014-06-28 | 2015-12-30 | Sunshine Lake Pharma Co., Ltd. | Compounds as hepatitis c virus (hcv) inhibitors and uses thereof in medicine |
| WO2016004513A1 (en) * | 2014-07-11 | 2016-01-14 | Simon Fraser University | Anti-bacterial pyruvate kinase modulator compounds, compositions, uses and methods |
| MY187540A (en) | 2014-08-01 | 2021-09-28 | Nuevolution As | Compounds active towards bromodomains |
| WO2016040588A1 (en) | 2014-09-11 | 2016-03-17 | Abbvie Inc. | Treatment of hcv by administering four different anti-hcv compounds with food |
| SI3207043T1 (sl) | 2014-10-14 | 2019-04-30 | Vitae Pharmaceuticals, Inc. | Dihidropirolopiridinovi inhibitorji za ROR-gama |
| US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
| US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| WO2016105547A1 (en) | 2014-12-24 | 2016-06-30 | Concert Pharmaceuticals, Inc. | Deuterated dasabuvir |
| RU2590952C1 (ru) * | 2015-05-26 | 2016-07-10 | Вячеслав Энгельсович Семёнов | Средство гепатопротекторного действия |
| WO2016196280A1 (en) | 2015-06-02 | 2016-12-08 | E I Du Pont De Nemours And Company | Heterocycle-substituted bicyclic pesticides |
| WO2017019828A1 (en) * | 2015-07-30 | 2017-02-02 | Bristol-Myers Squibb Company | Aryl substituted bicyclic heteroaryl compounds |
| WO2017024018A1 (en) | 2015-08-05 | 2017-02-09 | Vitae Pharmaceuticals, Inc. | Modulators of ror-gamma |
| CN108463458B (zh) | 2015-11-20 | 2022-02-01 | 生命医药有限责任公司 | ROR-γ的调节剂 |
| TW202220968A (zh) | 2016-01-29 | 2022-06-01 | 美商維它藥物有限責任公司 | ＲＯＲ－γ調節劑 |
| WO2017189978A1 (en) | 2016-04-28 | 2017-11-02 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
| WO2019023207A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | Inhibitors of rorϒ |
| CN107266373A (zh) * | 2017-08-01 | 2017-10-20 | 安徽拜善晟制药有限公司 | 一种原料药达沙布韦的制备方法 |
| JP7252973B2 (ja) | 2018-03-26 | 2023-04-05 | ノバルティス アーゲー | Ｎ－（３－（７Ｈ－ピロロ［２，３－ｄ］ピリミジン－４－イル）フェニル）ベンズアミド誘導体 |
| CN110483496B (zh) * | 2019-07-17 | 2021-05-04 | 杭州市西溪医院 | 一类具有尿嘧啶-苯并噻唑结构衍生物、其制备方法及抗hcv药物的应用 |
| WO2021053495A1 (en) * | 2019-09-16 | 2021-03-25 | Novartis Ag | Bifunctional degraders and their methods of use |
| EP3819006A1 (en) | 2019-11-05 | 2021-05-12 | Technische Universität Dresden | Compounds with thymine skeleton for use in medicine |
| CN111518036A (zh) * | 2020-04-29 | 2020-08-11 | 杭州勇诚睿生物科技有限公司 | 一种达沙布韦关键中间体的制备方法 |
| US12274700B1 (en) | 2020-10-30 | 2025-04-15 | Accencio LLC | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4239888A (en) * | 1974-11-04 | 1980-12-16 | Pfizer Inc. | 1-Phenyluracils |
| JPS60243017A (ja) * | 1984-05-16 | 1985-12-03 | Kyowa Hakko Kogyo Co Ltd | 抗けいれん組成物 |
| US5084084A (en) * | 1989-07-14 | 1992-01-28 | Nissan Chemical Industries Ltd. | Uracil derivatives and herbicides containing the same as active ingredient |
| AU627906B2 (en) * | 1989-07-14 | 1992-09-03 | Nissan Chemical Industries Ltd. | Uracil derivatives and herbicides containing the same as active ingredient |
| EP0442473B1 (en) | 1990-02-15 | 1998-08-19 | Takeda Chemical Industries, Ltd. | Pyrimidinedione derivatives, their production and use |
| NL9001075A (OSRAM) * | 1990-05-04 | 1991-12-02 | Duphar Int Res | |
| EP0489480A1 (en) * | 1990-12-05 | 1992-06-10 | Nissan Chemical Industries Ltd. | Uracil derivatives and herbicides containing the same as active ingredient |
| JPH05213755A (ja) | 1992-02-07 | 1993-08-24 | Nikko Kyodo Co Ltd | 肝臓障害治療薬 |
| DE19528305A1 (de) | 1995-08-02 | 1997-02-06 | Bayer Ag | Substituierte Phenyluracile |
| US6380387B1 (en) * | 1999-12-06 | 2002-04-30 | Hoffmann-La Roche Inc. | 4-Pyrimidinyl-n-acyl-l phenylalanines |
| KR100522344B1 (ko) | 1999-12-06 | 2005-10-20 | 에프. 호프만-라 로슈 아게 | 4-피리미디닐-ｎ-아실-ｌ-페닐알라닌 |
| IL167955A (en) * | 2000-02-04 | 2007-10-31 | Sumitomo Chemical Co | Inilines are converted by troiril |
| RU2264395C2 (ru) * | 2000-02-04 | 2005-11-20 | Сумитомо Кемикал Компани, Лимитед | Производные урацила, гербицидная композиция, способ борьбы с сорняками и промежуточные продукты (варианты) |
| MY164523A (en) * | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| TW200505872A (en) * | 2003-06-13 | 2005-02-16 | Lg Life Science Ltd | Hepatitis C virus inhibitors |
| US7163937B2 (en) | 2003-08-21 | 2007-01-16 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| AR061570A1 (es) * | 2006-06-23 | 2008-09-03 | Smithkline Beecham Corp | Compuesto de glicina sustituido en el n heteroaromatico composicion farmaceutica que lo comprende, su uso para preparar un medicamento, procedimientos para preparar dicha composicion farmaceutica y para preparar el compuesto |
| CA2699989C (en) | 2007-09-17 | 2014-03-25 | Abbott Laboratories | N-phenyl-dioxo-hydro pyrimidines useful as hepatitis c virus (hcv) inhibitor |
| EP2222646B1 (en) | 2007-09-17 | 2014-01-22 | AbbVie Bahamas Ltd. | Uracil or thymine derivative for treating hepatitis c |
| DK2203431T3 (da) * | 2007-09-17 | 2011-11-21 | Abbott Lab | Antiinfektiøse pyrimidiner og anvendelser heraf |
| CN102099335A (zh) | 2008-07-23 | 2011-06-15 | 弗·哈夫曼-拉罗切有限公司 | 杂环抗病毒化合物 |
-
2008
- 2008-09-17 EP EP08831873.8A patent/EP2222646B1/en not_active Not-in-force
- 2008-09-17 MX MX2010002905A patent/MX2010002905A/es active IP Right Grant
- 2008-09-17 CN CN201210157072.8A patent/CN102746239B/zh not_active Expired - Fee Related
- 2008-09-17 PE PE2008001621A patent/PE20090705A1/es active IP Right Grant
- 2008-09-17 NZ NZ618277A patent/NZ618277A/en not_active IP Right Cessation
- 2008-09-17 MY MYPI2010001141A patent/MY162760A/en unknown
- 2008-09-17 BR BRPI0816994A patent/BRPI0816994B8/pt active IP Right Grant
- 2008-09-17 NZ NZ584720A patent/NZ584720A/en not_active IP Right Cessation
- 2008-09-17 KR KR1020157010052A patent/KR101660360B1/ko not_active Expired - Fee Related
- 2008-09-17 CL CL2008002794A patent/CL2008002794A1/es unknown
- 2008-09-17 CA CA2976793A patent/CA2976793A1/en not_active Abandoned
- 2008-09-17 TW TW103110394A patent/TWI534137B/zh not_active IP Right Cessation
- 2008-09-17 SG SG2012060521A patent/SG183733A1/en unknown
- 2008-09-17 PA PA20088796201A patent/PA8796201A1/es unknown
- 2008-09-17 TW TW097135721A patent/TWI437994B/zh active
- 2008-09-17 UA UAA201302816A patent/UA117800C2/uk unknown
- 2008-09-17 NZ NZ600371A patent/NZ600371A/en unknown
- 2008-09-17 PE PE2012002073A patent/PE20130209A1/es not_active Application Discontinuation
- 2008-09-17 CN CN200880107764.3A patent/CN101801935B/zh not_active Expired - Fee Related
- 2008-09-17 AR ARP080104045A patent/AR070027A1/es active IP Right Grant
- 2008-09-17 WO PCT/US2008/076576 patent/WO2009039127A1/en not_active Ceased
- 2008-09-17 KR KR1020107008431A patent/KR101552474B1/ko active Active
- 2008-09-17 EP EP13193524.9A patent/EP2725015A1/en not_active Withdrawn
- 2008-09-17 ES ES08831873.8T patent/ES2453591T3/es active Active
- 2008-09-17 CA CA2699981A patent/CA2699981C/en not_active Expired - Fee Related
- 2008-09-17 AU AU2008302448A patent/AU2008302448B2/en active Active
- 2008-09-17 JP JP2010525102A patent/JP5734654B2/ja not_active Expired - Fee Related
- 2008-09-17 RU RU2010114828/04A patent/RU2543620C2/ru not_active IP Right Cessation
- 2008-09-17 IN IN5113DEN2012 patent/IN2012DN05113A/en unknown
- 2008-09-17 UY UY31344A patent/UY31344A1/es active IP Right Grant
-
2010
- 2010-03-15 GT GT201000061A patent/GT201000061A/es unknown
- 2010-03-16 CR CR11316A patent/CR11316A/es unknown
- 2010-03-16 CO CO10030957A patent/CO6260076A2/es active IP Right Grant
- 2010-03-16 MX MX2012004779A patent/MX338555B/es unknown
- 2010-03-16 IL IL204547A patent/IL204547A/en active Protection Beyond IP Right Term
- 2010-03-16 DO DO2010000084A patent/DOP2010000084A/es unknown
- 2010-03-17 US US12/725,689 patent/US8415351B2/en not_active Expired - Fee Related
- 2010-12-21 DO DO2010000396A patent/DOP2010000396A/es unknown
-
2012
- 2012-04-03 US US13/438,609 patent/US8685991B2/en not_active Expired - Fee Related
- 2012-06-08 ZA ZA2012/04223A patent/ZA201204223B/en unknown
- 2012-06-08 ZA ZA2012/04224A patent/ZA201204224B/en unknown
- 2012-08-06 AR ARP120102873A patent/AR087472A2/es unknown
- 2012-10-11 JP JP2012225875A patent/JP2013049681A/ja active Pending
-
2013
- 2013-02-01 RU RU2013104270/04A patent/RU2599635C2/ru not_active IP Right Cessation
- 2013-02-06 CL CL2013000372A patent/CL2013000372A1/es unknown
- 2013-02-25 PH PH12013500365A patent/PH12013500365A1/en unknown
-
2014
- 2014-03-31 US US14/230,965 patent/US9095590B2/en not_active Expired - Fee Related
-
2015
- 2015-05-08 CR CR20150238A patent/CR20150238A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL204547A (en) | Oracil derivative for the treatment of hepatitis c | |
| IL257418A (en) | Methods for treating addiction | |
| ZA200906129B (en) | Compounds for the treatment of hepatitis c | |
| PL2754660T3 (pl) | Pochodne pirydazynonowe | |
| ZA201105720B (en) | Compounds for the treatment of hepatitis c | |
| EP2343066A4 (en) | THERAPEUTIC AGENT FOR HEPATITIS C | |
| IL204736A0 (en) | Heterocyclic antiviral compounds | |
| ZA200909054B (en) | Pyridazinone Derivatives | |
| IL205611A0 (en) | Quinoxaline-containing compounds as hepatitis c virus inhibitors | |
| IL209696A0 (en) | Heterocyclic antiviral compounds | |
| IL200661A0 (en) | Heterocyclic antiviral compounds | |
| ZA200901668B (en) | 2-(heterocyclylbenzyl)pyridazinone derivatives | |
| ZA201105440B (en) | Pyridazinone derivatives | |
| IL212636A0 (en) | Pyridazinone derivatives | |
| EP2123631A4 (en) | PROCESS FOR PRODUCTION OF -ALCOXYPROPIONAMIDE | |
| ZA201008330B (en) | Pyridazinone derivatives | |
| ZA201003815B (en) | Heterocyclic antiviral compounds | |
| PL2209784T3 (pl) | Związki do leczenia zapalenia wątroby typu C | |
| ZA201000923B (en) | Compounds for the treatment of hepatitis c | |
| ZA201104362B (en) | Heterocyclic antiviral compounds | |
| EP2163554A4 (en) | PYRIMIDODIAZEPINONE DERIVATIVE | |
| EP1986651A4 (en) | USE OF A PYRIMIDINE DERIVATIVE FOR THE PREVENTION OR TREATMENT OF HEPATITIS C | |
| IL236462A0 (en) | triazine derivative compounds | |
| ZA200802123B (en) | Benzodiazepine derivatives for treating hepatitis C infection | |
| ZA201000867B (en) | Methods for treating dependence |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EXTF | Application for patent extension filed |
Filing date: 20150528 |
|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| PEL | Intention of commissioner to extend period of protection |
Free format text: PRODUCT NAME: DASABUVIR Extension date: 20281219 |
|
| KB | Patent renewed |